268678 HIV testing among financially-disadvantaged women diagnosed with cervical cancer in South Carolina

Monday, October 29, 2012

Lisa Wigfall, PhD, MA, BSMT (ASCP) , Institute for Partnerships to Eliminate Health Disparities, University of South Carolina - Arnold School of Public Health (Department of Health Services Policy and Management), Columbia, SC
Heather M. Brandt, PhD, CHES , Arnold School of Public Health, University of South Carolina, Columbia, SC
Sharon Bond, PhD , College of Nursing, Medical University of South Carolina, Charleston, SC
Heather Kirby , Office of Research and Statistics, South Carolina State Budget and Control Board, Columbia, SC
Wayne A. Duffus, MD, PhD , HIV and STD Medicine, South Carolina Department of Health & Environmental Control, Columbia, SC
Saundra Glover, MBA, PhD , Institute for Partnerships to Eliminate Health Disparities, University of South Carolina - Arnold School of Public Health, Columbia, SC
James R. Hebert, ScD , Cancer Prevention and Control Program, University of South Carolina, Columbia, SC
The purpose was to describe HIV testing conducted among women diagnosed with cervical cancer (CxCa). CxCa is an HIV/AIDS-associated cancer and more common among HIV-positive women because of sexually transmitted human papillomavirus (HPV) infection and immunocompromised status. This was an observational study of South Carolina women identified from linking Medicaid claims and Breast and Cervical Cancer Program (BCCP) databases. The International Classification of Diseases for Oncology, 3rd Edition (ICD-O-3) CxCa diagnosis code (C530-C539) was used to identify 282 women diagnosed with CxCa. Participants were enrolled in Medicaid for at least one month in the first year of being enrolled in the BCCP and >9 months in each subsequent year between January 1, 2005-December 31, 2009. Current Procedural Terminology (CPT) codes for a rapid (86701-92, 86702-92, 86703-92) or blood (86689, 87390, 87534, 87535, 87536) HIV test was used to determine if an HIV test had been ordered since CxCa diagnosis. The sample was 54.6% white (Median age = 49 years) and 39.4% black (Median age = 52 years). Those less than aged 40 were excluded (24.8%; n=70) due to lower CxCa incidence. Only 7.5% (n=16) of the remaining 212 women had been tested for HIV since being diagnosed with CxCa. Routine HIV testing is recommended for persons aged 13-64 if HIV status is unknown. Knowledge of the HIV status of women diagnosed with CxCa is important to afford prompt linkage to specialty care that will improve cancer and overall health outcomes.

Learning Areas:
Public health or related research
Social and behavioral sciences

Learning Objectives:
1) Describe the connection between HIV and cervical cancer (as well as other HIV/AIDS-associated types of cancer); 2) Discuss the implications of HIV testing in improved cervical cancer and overall health outcomes; and 3) Identify the challenges of making HIV testing routine among women diagnosed with cervical cancer.

Keywords: HIV/AIDS, Cervical Cancer

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Co-PI; directed data analysis
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.